Paraquat Lawsuit Settlement Amounts in 2026
What benchmarks exist, what affects case value, and why Pennsylvania state court cases are projected to recover more than federal MDL averages.
What we cannot promise
No reputable paraquat firm will promise you a specific dollar amount. Case value depends on individual facts that are different for every claimant — exposure documentation, age, disease severity, economic damages, and venue. Any attorney who promises a specific number is being dishonest. With that caveat, the public benchmarks below help frame realistic expectations.
The $187.5 million Syngenta prior settlement
The Syngenta $187.5 million prior settlement provides the most-cited public benchmark for paraquat case valuation. The settlement resolved a defined inventory of high-quality cases and operated through court-supervised allocation. While individual case payouts were confidential, the overall structure became a reference point for subsequent negotiations.
The January 2026 Philadelphia bellwether
The first paraquat bellwether case in the Philadelphia Court of Common Pleas mass tort program settled confidentially on the courthouse steps in January 2026, minutes before jury selection. The dollar figure is sealed. What is not sealed is the meaning: defendants pay courthouse-steps premiums to keep hostile jury verdicts off the books. The January 2026 settlement effectively re-priced the entire Philadelphia paraquat docket and is the single most influential data point in current settlement valuation discussions.
The April 2025 Syngenta settlement framework
In April 2025, Syngenta announced a settlement framework for a substantial portion of the federal MDL paraquat inventory. The framework operates through a qualified settlement fund administered with points-based allocation. The exact dollar-per-point matrix is confidential, but the structure rewards:
- Documented occupational exposure over multiple years
- Younger age at Parkinson's onset (longer expected disability)
- More advanced disease (higher Hoehn and Yahr stage or higher MDS-UPDRS scores)
- Clean differential diagnosis from a movement disorder specialist
- Significant economic losses (lost income, ongoing medical care)
- Absence of disqualifying comorbid conditions
The framework does not extinguish liability for cases that opt out, and it does not bind Chevron. Pennsylvania state court claimants with strong facts often consider whether to opt out and prosecute in Philadelphia.
Settlement tier framework (illustrative)
Mass tort settlements typically resolve through tiered allocations. For paraquat, an illustrative tier framework looks something like:
- Catastrophic tier — late-stage Parkinson's (Hoehn and Yahr 4–5), heavy occupational exposure, significant economic damages, younger age at onset
- Serious tier — confirmed Parkinson's (Hoehn and Yahr 2–3), well-documented exposure, meaningful economic damages
- Moderate tier — early-stage Parkinson's, documented exposure, modest economic damages
- Threshold tier — newly diagnosed Parkinson's with documented exposure but limited record of intensity or duration
These tiers are illustrative — actual allocation matrices are confidential and vary by program.
Factors that increase case value
- Pennsylvania state court venue rather than federal MDL — Philadelphia juries return higher verdicts in toxic tort cases
- Movement disorder specialist diagnosis rather than general neurologist
- Strong exposure documentation — applicator license records, payroll records, photographs, witness statements
- Young age at onset — longer expected disability and lost earning years
- No disqualifying differential diagnoses — essential tremor, drug-induced parkinsonism, atypical parkinsonisms
- Significant lost income — particularly for plaintiffs who were active workers at onset
- Ongoing medical care needs — physical therapy, occupational therapy, future surgical interventions
- Loss of consortium claims from spouses where state law allows
Why Pennsylvania state court is projected to recover more
Pennsylvania state court paraquat claims are widely expected to recover more, on average, than federal MDL claims. Three structural reasons:
- Faster pace through the Philadelphia Complex Litigation Center creates credible trial threat that drives settlement leverage
- Philadelphia jury composition has a documented history of higher plaintiff verdicts in mass tort cases
- Broader jurisdiction under PA's consent-by-registration doctrine permits self-selection into the highest-value forum
Full Pennsylvania advantage breakdown →
Gross vs net recovery
The headline settlement number is not what you take home. From the gross recovery, expect deductions for:
- Attorney fees — typically one-third contingency
- Case expenses — filing fees, expert witnesses, depositions, medical records
- Liens — health insurance, Medicare, Medicaid, VA benefits, hospital liens
- Medicare set-aside if required to fund future Parkinson's-related care
A skilled lien resolution team can substantially increase your net by negotiating lien reductions. Ask your lawyer for a net-recovery estimate, not just a gross figure. How contingency fees actually work →
No guarantees
Past results do not guarantee future outcomes. Every case is individual. The benchmarks above describe the publicly known landscape, not your specific case. The only way to get a realistic assessment of your case value is to talk to experienced paraquat counsel.